<DOC>
	<DOC>NCT01630876</DOC>
	<brief_summary>This study compares the anatomical and visual outcomes of patients with idiopathic epiretinal membrane(ERM) treated by vitrectomy and membrane peeling with or without subtenon triamcinolone acetonide injection</brief_summary>
	<brief_title>Outcomes of Vitrectomy Combined With Subtenon Triamcinolone Injection for the Idiopathic Epiretinal Membrane</brief_title>
	<detailed_description />
	<mesh_term>Epiretinal Membrane</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>1.The participant must have idiopathic epiretinal membrane 2.The participant must be willing and able to comply with the protocol. 1. The participant has idiopathic epiretinal membrane with other ocular vascular diseases such as Diabetes retinopathy, BRVO, etc. 2. The participant has any additional ocular diseases that have irreversibly compromised or could likely compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy, clinically significant diabetic macular edema, severe non proliferative diabetic retinopathy, or proliferative diabetic retinopathy. 3. The participant has had intraocular surgery (including lens replacement surgery). 4. The participant has a history of (within the last six months), or current ocular or periocular infection (including any history of ocular herpes zoster or simplex).</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Epiretinal membrane</keyword>
	<keyword>triamcinolone acetonide</keyword>
</DOC>